AGF Management Ltd. Cuts Position in Humana Inc. (NYSE:HUM)

AGF Management Ltd. decreased its holdings in Humana Inc. (NYSE:HUM) by 14.4% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 8,478 shares of the insurance provider’s stock after selling 1,431 shares during the period. AGF Management Ltd.’s holdings in Humana were worth $2,151,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Pzena Investment Management LLC grew its position in Humana by 44.0% in the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock valued at $915,736,000 after acquiring an additional 1,103,132 shares in the last quarter. FMR LLC grew its position in Humana by 23.4% in the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after acquiring an additional 643,291 shares in the last quarter. Thrivent Financial for Lutherans grew its position in Humana by 55.6% in the third quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider’s stock valued at $190,145,000 after acquiring an additional 214,535 shares in the last quarter. Retirement Systems of Alabama grew its position in Humana by 735.9% in the fourth quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock valued at $55,563,000 after acquiring an additional 192,801 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC acquired a new stake in Humana in the third quarter valued at approximately $50,102,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

HUM stock opened at $253.11 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a market capitalization of $30.55 billion, a price-to-earnings ratio of 25.44, a PEG ratio of 2.05 and a beta of 0.57. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The stock’s fifty day moving average is $271.37 and its two-hundred day moving average is $280.52.

Humana (NYSE:HUM) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, research analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.40%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio is currently 35.58%.

Insider Activity at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

HUM has been the subject of several recent research reports. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Piper Sandler increased their price objective on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. JPMorgan Chase & Co. decreased their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. Truist Financial raised their price target on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Finally, Morgan Stanley decreased their price target on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Nineteen research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.